ArticleWorld journal of gastrointestinal surgery2024
Dexmedetomidine in colon cancer surgery: Evaluating its impact and efficacy.
Article in World journal of gastrointestinal surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present an editorial on an article that highlights the benefits of dexmedetomidine (Dex) in colon cancer surgeries, which have been thoroughly investigated in the referenced publication involving 117 subjects. Of these patients, 59 (group A) received Dex before anesthesia induction, while 58 (group B) received normal saline. Group A patients demonstrated several advantages over Group B, including lower propofol and remifentanil requirements, improved cerebral oxygenation as measured by regional cerebral oxygen saturation, better hemodynamic stability, and reduced incidence of postoperative cognitive dysfunction. In addition to its sedative and analgesic effects, Dex decreases the need for other anesthetic agents and enhances cerebral oxygenation in elderly patients undergoing colorectal surgery. The literature also supports the anti-inflammatory properties of Dex, which can reduce surgical stress and improve postoperative recovery in cancer patients. This editorial focuses on the various benefits of Dex, particularly its role in maintaining hemodynamic stability and facilitating early recovery in cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.